St. George's Vascular Institute, St. James' Wing, St. George's Hospital, London, United Kingdom.
J Vasc Surg. 2011 Oct;54(4):1100-1108.e6. doi: 10.1016/j.jvs.2011.04.038. Epub 2011 Jul 13.
Abdominal aortic aneurysms (AAA) are associated with inflammation, apoptosis, and matrix degradation. AAA tissue represents the end stage of disease, limiting its utility in identification of factors culpable for initiation of aneurysm development. Recent evidence suggests that AAAs are a local representation of a systemic disease of the vasculature. Morphologic and molecular changes, comparable to those found in the aneurysm wall, have been demonstrated in veins from patients with AAAs. Changes in the vascular tissue proteome of patients with AAAs were investigated, using inferior mesenteric vein (IMV), to gain insight into early molecular changes contributing to AAA development.
IMV was harvested from 16 patients with AAA and 16 matched controls. Whole IMV lysates were subjected to 2-D difference in gel electrophoresis (2D-DIGE) with quantitative densitometry. Protein spots differentially expressed in AAA were identified using mass spectrometry. Differential protein expression was validated by Western blotting and localized to cell type by immunohistochemistry (IHC).
Decreased levels of prohibitin (AAA, 2.00 ± 1.37; controls, 3.81 ± 1.39; 1.9-fold change; P = .02) AAA (7.33 ± 3.9; controls, 14.5 ± 5.6; 2-fold change; P = .001), along with relative increases in a cleaved fragment of vimentin (AAA, 12.9 ± 9; controls, 6.9 ± 4.7; 2-fold change; P = .11) were identified in AAA patients. All proteins were localized to the vascular smooth muscle cells.
Proteins important in combating the injurious effects of oxidative stress and modulating the response to inflammation appear reduced in the vasculature of patients with AAA. These changes may represent early events in AAA formation. Enhancing expression of these proteins might offer a novel therapeutic avenue to inhibit AAA development.
腹主动脉瘤(AAA)与炎症、细胞凋亡和基质降解有关。AAA 组织代表疾病的终末阶段,限制了其在确定导致动脉瘤发展的因素方面的应用。最近的证据表明,AAA 是血管系统全身性疾病的局部表现。在 AAA 患者的静脉中已经证明了与动脉瘤壁中发现的类似的形态和分子变化。通过研究肠系膜下静脉(IMV),研究 AAA 患者血管组织蛋白质组的变化,以深入了解导致 AAA 发展的早期分子变化。
从 16 例 AAA 患者和 16 例匹配对照中采集 IMV。对整个 IMV 裂解物进行二维差异凝胶电泳(2D-DIGE)和定量密度测定。使用质谱法鉴定 AAA 中差异表达的蛋白质斑点。通过 Western 印迹和免疫组织化学(IHC)验证差异蛋白表达,并对细胞类型进行定位。
抑制素(AAA,2.00 ± 1.37;对照,3.81 ± 1.39;1.9 倍变化;P =.02)和相对增加的波形蛋白裂解片段(AAA,7.33 ± 3.9;对照,14.5 ± 5.6;2 倍变化;P =.001)水平降低在 AAA 患者中鉴定出。所有蛋白质均定位于血管平滑肌细胞。
在 AAA 患者的血管中,对抗氧化应激损伤作用和调节炎症反应的重要蛋白质似乎减少。这些变化可能代表 AAA 形成的早期事件。增强这些蛋白质的表达可能为抑制 AAA 发展提供新的治疗途径。